{"id":140759,"date":"2023-02-09T10:08:43","date_gmt":"2023-02-09T15:08:43","guid":{"rendered":"https:\/\/44.250.171.167\/?p=140759"},"modified":"2023-02-09T10:08:44","modified_gmt":"2023-02-09T15:08:44","slug":"aurobindo-pharma-limited-nse-auropharma-q3-fy23-results-out-total-income-rises-7-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-nse-auropharma-q3-fy23-results-out-total-income-rises-7-yoy\/","title":{"rendered":"Aurobindo Pharma Limited (NSE: AUROPHARMA): Q3 FY23 Results Out; Total Income Rises 7% YoY"},"content":{"rendered":"\n

Aurobindo Pharma Limited (NSE: AUROPHARMA)<\/a> is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since grown to become one of the largest pharmaceutical companies in India, with a presence in over 150 countries. Aurobindo Pharma produces a wide range of generic and specialty pharmaceutical products, including active pharmaceutical ingredients, finished dosages, and biotechnology products. The company has a strong focus on research and development, and has several state-of-the-art manufacturing facilities in India and Europe. The company’s product portfolio includes treatments for a variety of therapeutic areas, including cardiovascular disease, CNS disorders, anti-retrovirals, and anti-malarials.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Aurobindo Pharma has released its Q3FY23 financial results. The company reported a revenue from operations of Rs 6,407.1 crore, which represents an increase of 6.7% YoY. The US formulation revenue showed a growth of 9.3% YoY to reach Rs 3,001.2 crore, while Europe formulation revenue increased by 0.4% YoY to Rs 1,701.2 crore. The growth markets revenue experienced a growth of 25.7% YoY, reaching Rs 498.9 crore. Additionally, the company’s ARV revenue improved by 61.3% YoY to reach Rs 251.2 crore. The API revenue was reported at Rs 954.6 crore.<\/p>\n\n\n\n

The company’s EBITDA before forex and other income was reported at Rs 954.4 crore, with an EBITDA margin of 14.9%. The quarter saw an accelerated spend in research and development, with R&D spend amounting to Rs 415.2 crore, or 6.5% of revenues. The company received final approval for 15 ANDAs, including 4 injectable products, from the US FDA. The net profit for the quarter stood at Rs 491.2 crore, an increase from the previous quarter’s net profit of Rs 409.4 crore. The Basic & Diluted EPS for the quarter was Rs 8.38 per share. The company’s board has approved an interim dividend of 300%, or Rs 3 per equity share of Rs 1 for the year FY23.<\/p>\n\n\n\n

In a statement, the Vice-Chairman and Managing Director of the company, Mr. K. Nithyananda Reddy, expressed his satisfaction with the company’s performance and stated their commitment to continuously innovate and differentiate. He mentioned that the company has increased its investments in Biosimilars and aims to sustain its momentum with new launches, improved cost efficiencies, and adherence to high standards of compliance.<\/p>\n","protected":false},"excerpt":{"rendered":"

Aurobindo Pharma Limited (NSE: AUROPHARMA) is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since grown to become one of the largest pharmaceutical companies in India, with a presence in over 150 countries. Aurobindo Pharma produces a wide range of generic and specialty pharmaceutical products, including active pharmaceutical […]<\/p>\n","protected":false},"author":1932,"featured_media":140760,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392,5747],"tags":[1408],"class_list":["post-140759","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","category-healthcare-stocks","tag-pharma-stocks"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":147899,"url":"https:\/\/alphastreet.com\/india\/alphagraph-aurobindo-pharma-ltd-nse-auropharma-q4fy23-results-out-total-income-rises-13-yoy\/","url_meta":{"origin":140759,"position":0},"title":"Alphagraph | Aurobindo Pharma Ltd (NSE: AUROPHARMA): Q4FY23 Results Out; Total Income rises 13% YoY.","author":"Divyansh_Kasana","date":"May 31, 2023","format":false,"excerpt":"Aurobindo Pharma is a leading pharmaceutical company primarily involved in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company specializes in the production of APIs, which are the key components of pharmaceutical formulations. Aurobindo Pharma also focuses on the development, manufacturing, and distribution\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/d8773e43-3b1c-4981-b19b-cf6d51a09aa9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":148570,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-driving-growth-in-the-pharmaceutical-industry\/","url_meta":{"origin":140759,"position":1},"title":"Aurobindo Pharma: Driving Growth in the Pharmaceutical Industry","author":"Divyansh_Kasana","date":"June 8, 2023","format":false,"excerpt":"Stock Data: TickerNSE: AUROPHARMAExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+2.46%YTD+54.04%Last 12 Months+26.40% Company Description: Aurobindo, a company based in Hyderabad since 1986, focuses on producing generic formulations and APIs. Most of Aurobindo's sales, around 90%, come from international markets. In the United States, the company is recognized as the fifth largest\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/06\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":125403,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-results-in-q2-2022\/","url_meta":{"origin":140759,"position":2},"title":"Earnings: Aurobindo Pharma results in Q2 2022","author":"Nishadkishore","date":"November 8, 2021","format":false,"excerpt":"Aurobindo Pharma (NSE: AUROPHARMA) reported its second-quarter 2022 earnings results today. The company had a consolidated net profit of \u20b9696.71 crores with a decline of 14% compared to the previous year. Consolidated total revenue from operations during the period was at \u20b95,941.92 crores compared to \u20b96,483.44 crores for the same\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133199,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy-2023-research-tear-sheet\/","url_meta":{"origin":140759,"position":3},"title":"Aurobindo Pharma Limited Q1 FY 2023 Research Tear Sheet","author":"sreerupa","date":"August 15, 2022","format":false,"excerpt":"Stock Data Ticker: AUROPHARMA Exchange :NSE and BSE Industry: Automobile Price Performance Last 7 days\u00a0\u00a0\u00a0 4.36% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -19.19% Last 12 months\u00a0\u00a0\u00a0\u00a0 -28.17% It will be beneficial to invest in the stocks of Aurobindo Pharma. The company enjoys a \u00a0healthy\u00a0ROE of\u00a021.49% ROE which is an\u00a0 important financial parameter. The company has\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180234,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-posts-q3-fy26-revenue-growth-on-europe-strength-margins-stable\/","url_meta":{"origin":140759,"position":4},"title":"Aurobindo Pharma Limited posts Q3 FY26 revenue growth on Europe strength; margins stable","author":"Staff Correspondent","date":"February 10, 2026","format":false,"excerpt":"Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804) reported higher revenue and profit for the quarter ended Dec. 31, 2025, supported by strong growth in Europe and stable performance in the U.S. base business, according to the company\u2019s revised Q3 FY26 investor presentation used for its analyst call. Q3 FY26 financial\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":133712,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":140759,"position":5},"title":"Aurobindo Pharma Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"September 2, 2022","format":false,"excerpt":"https:\/\/youtu.be\/b8g7f6BUs9Y Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q1 FY23 Earnings Concall Q&A Highlights: [00:08:34] Prakash Agarwal of Axis Capital asked about the price erosion trends. Ram Prasad Chairman replied that the company is seeing some kind of tapering and believes the price erosion in 1Q23 vs 4Q22 is 2%\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=140759"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140759\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/140760"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=140759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=140759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=140759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}